Private Advisor Group LLC Boosts Holdings in Sanofi (NASDAQ:SNY)

Private Advisor Group LLC grew its position in Sanofi (NASDAQ:SNY) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,338 shares of the company’s stock after acquiring an additional 1,339 shares during the period. Private Advisor Group LLC’s holdings in Sanofi were worth $3,016,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Manning & Napier Advisors LLC purchased a new stake in shares of Sanofi during the 2nd quarter worth $13,725,000. Mount Yale Investment Advisors LLC boosted its holdings in Sanofi by 44.3% during the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after buying an additional 12,806 shares in the last quarter. Jennison Associates LLC boosted its holdings in Sanofi by 18.9% during the first quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after buying an additional 30,115 shares in the last quarter. Sei Investments Co. increased its holdings in Sanofi by 9.3% in the first quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock valued at $26,926,000 after buying an additional 47,297 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in shares of Sanofi by 10.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 307,627 shares of the company’s stock valued at $14,951,000 after acquiring an additional 29,082 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ SNY opened at $54.36 on Tuesday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a fifty-two week low of $44.05 and a fifty-two week high of $58.97. The business has a fifty day moving average of $56.08 and a 200-day moving average of $51.84. The stock has a market cap of $137.96 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 1.55 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 20.59%. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period last year, the company earned $2.55 EPS. As a group, analysts predict that Sanofi will post 4.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on SNY. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Finally, Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.